Sahajanand Medical Technologies Pvt. Ltd. (SMT), India’s largest manufacturer of cardiovascular medical stents, has announced the opening of its new Research & Development Centre in Galway City, Ireland. SMT aims to attract global talent through this new facility in Ireland to diversify its product portfolio.
The company has significant investment plans to develop this R&D Centre. The core functions of SMT Ireland Centre would be R&D and logistics. The key on-going research projects at the facility are developing next generation of Stent and Advanced Balloon Catheter technology. The centre will have detailed and advanced research on developing next generation stent. It will be working on advanced balloon catheter and stent bifurcation application which will be a great help in complex cases. The centre will also be flexible from logistics point of view as it will be able to track and deliver the stents and other products in various parts of the world.
The Ireland centre also plans to develop new range of peripheral products along with guidewires and other coronary accessories. The R&D leadership team is in place now and more researchers are expected to join the team in the coming weeks.
Commenting on the launch, Ganesh Sabat, CEO of SMT, said, “We were pioneers amongst Indian medical device companies and have seen tremendous value in investing in research & development (R&D). Our early investments in R&D, beginning one and half decades ago, enabled us to make technology our key differentiator and develop a robust coronary stent for the world. Our core strength lies in our ability to excel in developing technologically complex products through focused teams.”
The launch of the centre was attended by Sean Kyne, Minister of State, and Noel Larkin, Mayor of Galway City. The launch was also attended by the SMT Head of Europe, Gaurav Goel and the SMT vice president of international sales & marketing, Ilancheran Uthirapathi.
This is a major investment by SMT to remain ahead of the curve in adopting latest technologies through advanced research and compete with global competitors. Our aim is to continue to provide the most advanced technology to our consumers at competitive prices hence aligning with our vision of ‘pledge to save millions’. With this centre, we hope to tap into the global talent pool and explore the possible adaptation into the Indian market and strengthen India as a medical device manufacturing hub. This will provide a big fillip to support our Prime Minister’s dream of Make in India in the medical device industry, said Sabat.
Established in the year 1998, SMT became the first indigenous player in India to successfully launch coronary stent. SMT is also the first company to get CE approval for DES with Biodegradable Polymers in the world. It is India's largest stent manufacturing company and sells its product in more than 60 countries across the world.